CN103932189A - 女性专用保健品 - Google Patents
女性专用保健品 Download PDFInfo
- Publication number
- CN103932189A CN103932189A CN201410176790.9A CN201410176790A CN103932189A CN 103932189 A CN103932189 A CN 103932189A CN 201410176790 A CN201410176790 A CN 201410176790A CN 103932189 A CN103932189 A CN 103932189A
- Authority
- CN
- China
- Prior art keywords
- powder
- percent
- health product
- raw materials
- women
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000036541 health Effects 0.000 title claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 61
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 14
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 13
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 13
- 244000020518 Carthamus tinctorius Species 0.000 claims description 12
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 12
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 241000219780 Pueraria Species 0.000 claims description 11
- 238000012856 packing Methods 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 9
- 235000008434 ginseng Nutrition 0.000 claims description 9
- 244000061520 Angelica archangelica Species 0.000 claims 4
- 241000208340 Araliaceae Species 0.000 claims 4
- 230000000694 effects Effects 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 15
- 240000005373 Panax quinquefolius Species 0.000 abstract description 11
- 210000001672 ovary Anatomy 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 240000000759 Lepidium meyenii Species 0.000 abstract description 2
- 235000000421 Lepidium meyenii Nutrition 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 235000012902 lepidium meyenii Nutrition 0.000 abstract description 2
- 230000028327 secretion Effects 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 230000009758 senescence Effects 0.000 abstract 1
- 241000125175 Angelica Species 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- HCOLPNRPCMFHOH-UHFFFAOYSA-N Prodigiosin Natural products CCCCCC1C=C(C=C/2N=C(C=C2OC)c3ccc[nH]3)N=C1C HCOLPNRPCMFHOH-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- TWFGRJUTAULJPZ-USZBIXTISA-N prodigiosin Chemical compound N1=C(C)C(CCCCC)=C\C1=C/C1=NC(C=2[N]C=CC=2)=C[C]1OC TWFGRJUTAULJPZ-USZBIXTISA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000496 anti-anoxic effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000011224 negative regulation of urine volume Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- -1 pulvis Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种女性专用保健品,由如下质量百分比例的原料制成:40~70%玛咖粉、9~30%西洋参粉、9~40%葛根粉、9~30%当归粉和2~20%红花粉,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。本发明的保健品具有能调节内分泌、保护卵巢,推迟更年期、补血调血、延缓衰老等显著效果,副作用小,可制为颗粒、粉剂、片剂或胶囊剂。
Description
技术领域
本发明涉及一种女性专用保健营养品。
背景技术
现在各种治疗内分泌失调、保护卵巢,推迟更年期、补血调血、缓衰老的保健品存在或效果不显著,或副作用大的缺点。
发明内容
本发明提供一种能调节内分泌、保护卵巢,推迟更年期、补血调血和延缓衰老的女性专用保健品。
本发明的技术解决方案是:
女性专用保健品,由如下质量百分比例的原料制成:40~70%玛咖粉、9~30%西洋参粉、9~40%葛根粉、9~30%当归粉和2~20%红花粉。将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
作为本发明优选的技术方案:
所述的女性专用保健品由如下质量百分比例的原料制成:玛咖粉60%、西洋参粉15%、葛根粉10%、当归粉10%和红花粉5%,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
所述的女性专用保健品由如下质量百分比例的原料制成:玛咖粉50%、西洋参粉18%、葛根粉12%、当归粉12%和红花粉8%,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
所述的女性专用保健品由如下质量百分比例的原料制成:玛咖粉40%、西洋参粉20%、葛根粉12%、当归粉18%和红花粉10%,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
玛咖(maca)原产于秘鲁中部基宁及帕斯科附近海拔4000米以上的安地斯山,色泽黄中带紫,类似萝卜,是山上唯一的十字花科独行菜属一年生或两年生草本植物,2003年被我所成功引种在滇西北,其质量与秘鲁玛咖相媲美。由于它富含有多种均衡合理的蛋白质、糖类、脂肪酸、氨基酸、多种矿物质、多种维生素和多种具有生物活性的次生代谢产物生物碱(玛咖烯、玛咖酰胺)、芥子油苷、挥发油成分、甾醇、牛磺酸、植物多酚、皂角苷等成份。因此,玛咖具备多种保健和治疗功能。
西洋参(学名:Panax quinquefolius)为五加科人参属植物的干燥根,其具能调节中枢神经系统的兴奋与抑制,以抑制较为突出;能抗疲劳、抗缺氧、增强机体适应能力;有抗心律失常、抗心肌缺血、增强心肌收缩力的作用;有促进肾上腺皮质激素分泌的作用;能增强机体免疫功能;有抗利尿及止血作用。
葛根粉主要有降脂、降压、降火、清热解毒、升阳解肌、解痉镇痛、透疹止泻、增加脑和冠状血糖、改善脑微循环等功效,是防治高血压、高血脂、冠心病、心绞痛、糖尿病、脑血栓、肠胃病等多种疾病的药品的重要原料,同时对女性美容健身、丰胸等具有特殊功效。
当归粉有活血补血、泽肤、生肌补血、调经止痛、润肠通便等功效。含有维生素A、维生素B12、维生素E及人体必需氨基酸等营养素,可增强人体新陈代谢和内分泌功能,防治面部干燥、脱屑、瘙痒等疾病,使皮肤光泽细嫩,还能增强肠胃吸收能力,刺激卵巢,对妇女延迟衰老有一定食疗作用。
红花具能活血通经,散淤止痛,用于闭经,痛经,恶露不行,症瘕痞块,跌扑损伤,疮疡肿痛;性温,味辛,活血通经、散瘀止痛。用于经闭、痛经、恶露不行、症瘕痞块、跌打损伤等功效。
本发明人通过近一年的反复试验,证明上述配比保健品具有如下的技术效果:
本发明的保健品可制为颗粒、粉剂、片剂或胶囊剂。经发明人试验和使用者效果观察发现,它能有效保护卵巢,推迟更年期、调节内分泌、补血调血和等显著效果,副作用小,还有利于改善亚健康者的健康状况。长期服用对女性增强皮肤光泽、 月经量增多、推迟更年期等症状有很大的改善。
为表明本发明在保健品中的应用效果,本发明人选36岁到65岁之间女性,进行观察,随机将50例作为应用观察对象,其各项改善情况及结果见下表1。
观察方法和效果评判标准如下:
1、女性专用保健品是0.25g/片的片剂,一次4片,一日两次,按疗程90天服用,且在观察期间停止服用其它保健品和药物。
2、观察方法
服药期间10天观察一次,包括症状、体征改善情况,不良反应。服用前后分别查血压、血脂、尿、大便常规及潜血,肝、肾功能。
3、服用效果评判标准
1、疗效标准
按照卫生部药政局关于“新药(中药)治疗高血压、高血脂症的临床研究指导原则”规定的疗效标准。
治愈:症状完全消失,各项指标降到正常值:
显效:临床主要症状明显减轻,各项指标降到接近正常值;
有效:主要症状减轻,各项指标降了50%以上;
无效:症状有所减轻,各项指标没有下降。
2、统计学方法
总有效率=治愈率十显效率+有效率
表1 调节内分泌、保护卵巢,推迟更年期的情况及结果
注释:服用组人群96%无不良反应发生。4%人群有口干、燥热、便秘等不同程度症状。
具体实施方式
实施例1女性专用保健品
由如下质量百分比例的原料制成:玛咖粉60%、西洋参15%、葛根粉10%、当归粉10%和红花粉5%,将全部原料分别洗后晒干,粉碎,再经研磨至过150目筛,混合均匀,按常规技术制成片剂,成品包装。
实施例 2女性专用保健品
由如下质量百分比例的原料制成:玛咖粉50%、西洋参粉18%、葛根粉12%、当归粉12%、红花粉8%,将全部原料分别洗后晒干,粉碎,再经研磨至过200目筛,混合均匀,按常规技术制成片剂,成品包装。
实施例 3女性专用保健品
由如下质量百分比例的原料制成:玛咖粉40%、西洋参20%、葛根粉12%、当归粉18%、红花粉10%,将全部原料分别洗后晒干,粉碎,再经研磨至过300目筛,混合均匀,按常规技术制成片剂,成品包装。
Claims (4)
1.女性专用保健品,其特征在于,由如下质量百分比例的原料制成:40~70%玛咖粉、9~30%西洋参粉、9~40%葛根粉、9~30%当归粉和2~20%红花粉,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
2.女性专用保健品,其特征在于,由如下质量百分比例的原料制成:玛咖粉60%、西洋参粉15%、葛根粉10%、当归粉10%和红花粉5%,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
3.女性专用保健品,其特征在于,由如下质量百分比例的原料制成:玛咖粉50%、西洋参粉18%、葛根粉12%、当归粉12%和红花粉8%,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
4.女性专用保健品,其特征在于,由如下质量百分比例的原料制成:玛咖粉40%、西洋参粉20%、葛根粉12%、当归粉18%和红花粉10%,将全部原料分别洗后晒干,粉碎,再经研磨至过150-300目筛,混合均匀,按常规技术制成片剂,成品包装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410176790.9A CN103932189A (zh) | 2014-04-29 | 2014-04-29 | 女性专用保健品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410176790.9A CN103932189A (zh) | 2014-04-29 | 2014-04-29 | 女性专用保健品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103932189A true CN103932189A (zh) | 2014-07-23 |
Family
ID=51180275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410176790.9A Pending CN103932189A (zh) | 2014-04-29 | 2014-04-29 | 女性专用保健品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103932189A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104382036A (zh) * | 2014-12-09 | 2015-03-04 | 重庆综艺营养科技有限责任公司 | 女性日用保健品 |
CN104886576A (zh) * | 2015-06-11 | 2015-09-09 | 江苏慧博生物科技有限公司 | 一种女性保健食品及其制备方法 |
CN105039112A (zh) * | 2015-09-14 | 2015-11-11 | 江苏慧博生物科技有限公司 | 一种玛咖养生保健酒及其制备方法 |
CN105770212A (zh) * | 2016-03-17 | 2016-07-20 | 南京多宝生物科技有限公司 | 一种玛咖片 |
CN108606326A (zh) * | 2018-05-10 | 2018-10-02 | 烟台金蕊女性用品有限公司 | 生殖健康保养平衡液 |
CN108703362A (zh) * | 2018-04-28 | 2018-10-26 | 广东说养自然医学技术有限公司 | 一种滋养卵巢保健压片及其制备方法 |
CN108902959A (zh) * | 2018-07-25 | 2018-11-30 | 安徽全康药业有限公司 | 一种滋补肝肾的玛咖保健食品及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103585261A (zh) * | 2013-11-16 | 2014-02-19 | 丽江玛咖生物科技有限公司 | 玛咖人参片及其制备方法 |
-
2014
- 2014-04-29 CN CN201410176790.9A patent/CN103932189A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103585261A (zh) * | 2013-11-16 | 2014-02-19 | 丽江玛咖生物科技有限公司 | 玛咖人参片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
彭怀仁: "《中医方剂大辞典 第四册》", 28 February 1995, article "当归红花汤" * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104382036A (zh) * | 2014-12-09 | 2015-03-04 | 重庆综艺营养科技有限责任公司 | 女性日用保健品 |
CN104382036B (zh) * | 2014-12-09 | 2016-04-27 | 重庆综艺营养科技有限责任公司 | 女性日用保健品 |
CN104886576A (zh) * | 2015-06-11 | 2015-09-09 | 江苏慧博生物科技有限公司 | 一种女性保健食品及其制备方法 |
CN105039112A (zh) * | 2015-09-14 | 2015-11-11 | 江苏慧博生物科技有限公司 | 一种玛咖养生保健酒及其制备方法 |
CN105770212A (zh) * | 2016-03-17 | 2016-07-20 | 南京多宝生物科技有限公司 | 一种玛咖片 |
CN108703362A (zh) * | 2018-04-28 | 2018-10-26 | 广东说养自然医学技术有限公司 | 一种滋养卵巢保健压片及其制备方法 |
CN108606326A (zh) * | 2018-05-10 | 2018-10-02 | 烟台金蕊女性用品有限公司 | 生殖健康保养平衡液 |
CN108902959A (zh) * | 2018-07-25 | 2018-11-30 | 安徽全康药业有限公司 | 一种滋补肝肾的玛咖保健食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103932189A (zh) | 女性专用保健品 | |
CN102716263B (zh) | 一种玛咖、人参和枸杞组合物及其应用 | |
US20190328817A1 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
CN102091315A (zh) | 生姜与乌梅组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN102640829B (zh) | 具有改善心肌缺血功能的茶膏及其制备方法 | |
CN108618126A (zh) | 一种中药复方减肥特殊膳食食品及其制备方法 | |
CN109663021B (zh) | 具有抗氧化功能的组合物、制备方法及应用 | |
CN104173517B (zh) | 治疗原发性三叉神经痛的中药制剂及制备方法 | |
KR20170143235A (ko) | 연골재생 및 골관절염 치료용 생약조성물 | |
CN105030858A (zh) | 一种锁阳保健片及其制备方法 | |
CN105168567A (zh) | 玛咖保健组合物 | |
CN102091313B (zh) | 紫苏叶与生姜组合物、其制备方法及其在制备癌症放、化疗中减毒增效药物中的用途 | |
CN104432052A (zh) | 一种能抗疲劳防衰老的保健胶囊及其制备方法 | |
CN107137416A (zh) | 一种防治非小细胞肺癌的药物组合物 | |
CN101623044A (zh) | 一种中药乌鸡蛋的生产方法 | |
CN103005467A (zh) | 一种保肝营养组合物及其保肝营养食品 | |
CN102631482A (zh) | 一种具有防治糖尿病及并发症的中药组合物 | |
CN105029413A (zh) | 玛咖保健组合物 | |
CN104800600A (zh) | 一种治疗高血压的药物 | |
CN110122571A (zh) | 一种具有抗疲劳功能的速溶粉及其制备方法 | |
CN108552432A (zh) | 一种提高蛋鸡产蛋率的蛋鸡饲料及其制备方法 | |
CN102132876B (zh) | 含杜仲粉料的混合物及其制备方法 | |
CN105148030A (zh) | 玛咖保健组合物 | |
CN105168952A (zh) | 一种复方玛咖保健品 | |
CN105168954A (zh) | 一种保健组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140723 |